Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
48°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amneal Pharmaceuticals Inc
(NY:
AMRX
)
5.870
UNCHANGED
Last Price
Updated: 7:00 PM EST, Dec 26, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amneal Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
Next >
Amneal to Present Results From the Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 at the 2022 American Academy of Neurology Annual Meeting
March 24, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill
March 18, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Amneal Awarded Sub-License to Manufacture and Commercialize Generic Version of Co-Packaged Nirmatrelvir and Ritonavir in 95 Low- and Middle-Income Countries
March 17, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Pharmaceuticals's Return On Capital Employed Insights
March 08, 2022
Amneal Pharmaceuticals (NYSE:AMRX) brought in sales totaling $536.90 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 235.83%, resulting...
Via
Benzinga
Amneal Pharma's Q4 Earnings Fall Short Of Expectations, Sees FY22 Sales Growth Of 7%
March 02, 2022
Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q4 revenue of $537 million, an increase of 5% Y/Y, marginally missing the consensus of $537.35 million. The increase was...
Via
Benzinga
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
March 02, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label...
Via
Benzinga
Recap: Amneal Pharmaceuticals Q4 Earnings
March 02, 2022
Amneal Pharmaceuticals (NYSE:AMRX) reported its Q4 earnings results on Wednesday, March 2, 2022 at 06:00 AM. Here's what investors need to know about the announcement....
Via
Benzinga
Amneal Pharmaceuticals's Earnings: A Preview
March 01, 2022
Amneal Pharmaceuticals (NYSE:AMRX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-02. Here's what investors need to know before the announcement....
Via
Benzinga
Earnings Scheduled For March 2, 2022
March 02, 2022
Companies Reporting Before The Bell • SIGNA Sports United (NYSE:SSU) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million. •...
Via
Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
Amneal Expands Injectables Portfolio with 4 New Products
February 17, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Report Fourth Quarter and Full Year 2021 Results on March 2, 2022
February 04, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets
January 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,...
Via
Benzinga
Amneal's $83M Saol Acquisition Deal Expands Its Neurology Presence Into Spasticity
January 05, 2022
Amneal Pharmaceuticals Inc (NYSE: AMRX) has agreed to acquire Saol's Baclofen franchise, including Lioresal, Lyvispah, and a pipeline product under development for $...
Via
Benzinga
Amneal Acquires Saol Therapeutics’ Baclofen Franchise
January 05, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Virtually Participate at the 40th Annual J.P. Morgan Healthcare Conference
December 21, 2021
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
December 17, 2021
Gainers GBS (NASDAQ:GBS
Via
Benzinga
TherapeuticsMD, Amneal Settle US Patent Litigation For Bijuva
December 08, 2021
TherapeuticsMD Inc (NASDAQ: TXMD) has settled the previously disclosed U.S. patent litigation for Bijuva with Amneal Pharmaceuticals Inc (NYSE: AMRX)....
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom
December 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
Amneal Receives Approval for Difluprednate Ophthalmic Emulsion
November 19, 2021
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Virtually Participate at Upcoming Investor Conferences
November 12, 2021
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Pharmaceuticals, inc (AMRX) Q3 2021 Earnings Call Transcript
November 03, 2021
AMRX earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Amneal Posts Mixed Bag Q3 Earnings; Acquires Puniska To Bolster Injectable Business
November 03, 2021
Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q3 revenue of $529 million, a marginal increase of 2% Y/Y, missing the consensus of $545.06 million. The increase was driven...
Via
Benzinga
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
November 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...
Via
Benzinga
Topics
Retirement
Exposures
Pension
Amneal Reports Third Quarter 2021 Financial Results
November 03, 2021
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Releases Inaugural Corporate Responsibility Report Highlighting Our Impact as a Socially Responsible Company
November 02, 2021
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Launches Generic Dexamethasone Following ANDA Approval by FDA
October 27, 2021
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Mark Cuban-Owned Company To Launch Pharmacy Benefit Management Services
October 25, 2021
Billionaire investor Mark Cuban is funding a new company focused on selling generic pharmaceuticals at a transparent fixed-rate markup. What Happened: The Mark Cuban Cost Plus...
Via
Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Amneal to Report Third Quarter 2021 Results on November 3, 2021
October 06, 2021
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.